-
-
-
AACR 2025 China ADC Achievements Overview
AACR
Explore key highlights from AACR 2025, where Chinese biotech firms showcased breakthroughs in ADC therapies, including dual-target, dual-payload innovations and promising clinical outcomes in solid tumor treatments.
-
PD-(L)1 Resistance Hope
PD-1
Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
-
Innovative Drugs: The Changing Times
FDA
Recent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
-
Hengrui Pharmaceutical ADC Drug Overview
Hengrui
Hengrui has emerged as a leading force in ADC drug development, with a deep pipeline of 12 ADC drugs in clinical trials. Its proprietary HRMAP? platform and strategic innovations in targeting toxins and drug conjugation offer promising breakthroughs.
藁城市|
忻城县|
奉贤区|
永新县|
阿拉善右旗|
荔浦县|
禹城市|
潞城市|
榆林市|
英山县|
古交市|
汉源县|
太湖县|
南充市|
鸡西市|
石渠县|
南汇区|
腾冲县|
宁安市|
揭东县|
宁晋县|
凤台县|
元谋县|
怀柔区|
沂源县|
望谟县|
北安市|
苍山县|
会理县|
博客|
饶河县|
保靖县|
陕西省|
双辽市|
龙口市|
芦山县|
马龙县|
云林县|
乌拉特中旗|
唐河县|
垦利县|